
Weekly self-injection improves generalized myasthenia gravis symptoms
Clinical takeaway: For adults with AChR antibody–positive generalized myasthenia gravis, once-weekly subcutaneous gefurulimab produced clinically meaningful improvements within weeks. Longer-term







